Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
BörsenkürzelDXR
Name des UnternehmensDaxor Corp
IPO-datumJul 25, 1983
CEOMr. Michael Richard Feldschuh
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeJul 25
AddresseSuite 7120
StadtNEW YORK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl10118
Telefon12122440555
Websitehttps://www.daxor.com/
BörsenkürzelDXR
IPO-datumJul 25, 1983
CEOMr. Michael Richard Feldschuh
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten